Brokerages expect that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will announce earnings of ($0.49) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.50). Spring Bank Pharmaceuticals reported earnings of ($0.33) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 48.5%. The business is expected to report its next quarterly earnings results on Monday, March 9th.
On average, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($1.52) per share for the current year. For the next year, analysts forecast that the business will post earnings of ($2.11) per share, with EPS estimates ranging from ($2.34) to ($1.88). Zacks’ EPS averages are an average based on a survey of research analysts that cover Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Thursday, November 7th. The company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.19.
Several institutional investors have recently added to or reduced their stakes in SBPH. Hikari Power Ltd boosted its stake in shares of Spring Bank Pharmaceuticals by 162.3% during the 3rd quarter. Hikari Power Ltd now owns 160,914 shares of the company’s stock worth $554,000 after purchasing an additional 99,578 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Spring Bank Pharmaceuticals by 255.6% during the 2nd quarter. Renaissance Technologies LLC now owns 131,200 shares of the company’s stock worth $484,000 after purchasing an additional 94,300 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter worth about $230,000. Morse Asset Management Inc boosted its position in shares of Spring Bank Pharmaceuticals by 256.8% in the third quarter. Morse Asset Management Inc now owns 42,935 shares of the company’s stock worth $148,000 after acquiring an additional 30,900 shares during the last quarter. Finally, Tiedemann Advisors LLC boosted its position in shares of Spring Bank Pharmaceuticals by 6.2% in the third quarter. Tiedemann Advisors LLC now owns 437,589 shares of the company’s stock worth $1,505,000 after acquiring an additional 25,540 shares during the last quarter. 39.14% of the stock is currently owned by institutional investors.
Shares of Spring Bank Pharmaceuticals stock traded down $0.17 during mid-day trading on Wednesday, hitting $3.78. 44,329 shares of the stock were exchanged, compared to its average volume of 50,183. Spring Bank Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $11.90. The stock has a market capitalization of $63.12 million, a price-to-earnings ratio of -2.02 and a beta of 0.71. The company has a 50-day simple moving average of $3.23 and a 200 day simple moving average of $4.12. The company has a current ratio of 12.18, a quick ratio of 12.18 and a debt-to-equity ratio of 0.52.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Further Reading: Moving Average Convergence Divergence (MACD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.